- Home
- VERA vs PTGX Comparison
VERA vs PTGX Comparison
Compare VERA & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERA
- PTGX
- Stock Information
- Founded
- VERA 2016
- PTGX 2006
- Country
- VERA United States
- PTGX United States
- Employees
- VERA N/A
- PTGX N/A
- Industry
- VERA Biotechnology: Pharmaceutical Preparations
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- VERA Health Care
- PTGX Health Care
- Exchange
- VERA Nasdaq
- PTGX Nasdaq
- Market Cap
- VERA 1.4B
- PTGX 3.7B
- IPO Year
- VERA 2021
- PTGX 2016
- Fundamental
- Price
- VERA $24.24
- PTGX $58.38
- Analyst Decision
- VERA Buy
- PTGX Strong Buy
- Analyst Count
- VERA 8
- PTGX 9
- Target Price
- VERA $64.29
- PTGX $70.44
- AVG Volume (30 Days)
- VERA 1.8M
- PTGX 915.6K
- Earning Date
- VERA 11-06-2025
- PTGX 11-06-2025
- Dividend Yield
- VERA N/A
- PTGX N/A
- EPS Growth
- VERA N/A
- PTGX N/A
- EPS
- VERA N/A
- PTGX 0.80
- Revenue
- VERA N/A
- PTGX $209,180,000.00
- Revenue This Year
- VERA N/A
- PTGX N/A
- Revenue Next Year
- VERA N/A
- PTGX $185.11
- P/E Ratio
- VERA N/A
- PTGX $72.62
- Revenue Growth
- VERA N/A
- PTGX N/A
- 52 Week Low
- VERA $18.53
- PTGX $33.31
- 52 Week High
- VERA $51.61
- PTGX $61.89
- Technical
- Relative Strength Index (RSI)
- VERA 57.93
- PTGX 53.07
- Support Level
- VERA $23.69
- PTGX $54.50
- Resistance Level
- VERA $25.29
- PTGX $60.40
- Average True Range (ATR)
- VERA 1.26
- PTGX 2.68
- MACD
- VERA 0.17
- PTGX -0.12
- Stochastic Oscillator
- VERA 74.64
- PTGX 52.50
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.